TB-500 is marketed as a tissue-repair peptide, but the human evidence behind that claim is absent. FDA describes the commonly intended molecule as an acetylated seven-amino-acid fragment of thymosin beta-4. Cell and animal experiments involving that sequence or the full 43-amino-acid parent molecule report effects on actin, cell migration and wound models. They do not establish that commercial TB-500 heals human tendons, muscles or wounds. FDA's 2026 assessment found no human clinical study of TB-500 for any condition, while WADA expressly prohibits it in sport.
What is TB-500?
Thymosin beta-4, or Tβ4, is a naturally occurring 43-amino-acid peptide found in many cells and body fluids. It binds monomeric actin and participates in cytoskeletal regulation. TB-500 is generally described as Ac-LKKTETQ, an N-terminally acetylated seven-amino-acid sequence corresponding to residues 17 to 23 in Tβ4.
The name itself is a problem. TB-500 is a common name, not a standardized United States Adopted Name. In its July 2026 briefing, FDA reported that multiple salts, derivatives and even different active moieties are sold under the same label. A study of Ac-LKKTETQ therefore cannot validate every vial labeled TB-500.
TB-500 is also unrelated to BPC-157 despite both being promoted for "repair." They have different sequences, proposed mechanisms and evidence gaps.
Why researchers study the LKKTETQ sequence
The LKKTETQ region overlaps the actin-binding domain of full-length Tβ4. Research has linked Tβ4 and fragments to cell migration, angiogenesis, inflammatory signaling and extracellular-matrix responses.
In a 2003 animal study, full-length Tβ4 and a synthetic LKKTETQ peptide were tested in diabetic and aged mouse wound models. The fragment promoted dermal wound repair in aged animals. More recent cell research has examined the sequence in human hepatic stellate cells and found changes in proliferation, migration and signaling under laboratory conditions.
These experiments demonstrate biological activity. Translation to a human injury still requires answers about:
- absorption and distribution from the intended product and route;
- effective tissue exposure;
- clinically meaningful healing, pain and function;
- effects on abnormal angiogenesis, fibrosis and cancer biology;
- immune responses, impurities and repeated-use safety.
No animal wound model can answer all five.
The decisive human-evidence finding
FDA's 2026 review searched the nominated evidence and published medical literature for TB-500 in wound healing. It found no clinical studies in which TB-500 was administered to people to treat wounds or any other disease or condition. The agency concluded that there was insufficient evidence to evaluate effectiveness.
That finding is more informative than the number of preclinical papers. It means claims such as "clinically proven recovery," "human healing peptide" or "established injury protocol" are unsupported for TB-500 itself.
| Evidence sometimes cited for TB-500 | What the study actually concerns | Why transfer is invalid |
|---|---|---|
| Mouse dermal-wound research | Full Tβ4 or a defined short sequence in animals | Not a controlled human injury trial |
| Cell-migration experiments | Isolated cells under selected laboratory conditions | No patient-level healing or safety outcome |
| Full-length Tβ4 eye-drop trial | Topical 43-amino-acid thymosin beta-4 formulation | Different molecule, formulation, tissue and clinical purpose |
| Personal recovery stories | Uncontrolled, often with rehabilitation and other interventions | Natural recovery and confounding cannot be separated |
Why full-length thymosin beta-4 trials do not prove TB-500
A randomized phase 2 study evaluated a sterile ophthalmic solution containing full-length Tβ4 in 72 people with dry eye. Neither primary endpoint reached statistical significance, although some secondary eye measures favored the active group. This is legitimate human research on a defined formulation.
It is not evidence for systemic TB-500. Full-length Tβ4 and a seven-residue fragment differ in size and potentially in binding, stability, distribution and biological activity. Eye drops act at a local ocular surface, while an injection promoted for tendon repair creates a different exposure. Even a positive full-length Tβ4 eye study would not bridge those gaps.
This molecule-formulation-indication rule also applies across the wider peptide research library: related biology is not product approval. The defined, indication-specific evidence for tesamorelin shows what a very different clinical package looks like.
Safety and product-quality concerns
FDA's compounding safety-risk page states that thymosin beta-4 fragment, also known as TB-500, may present immunogenicity risk because of aggregation and peptide-related impurities. The agency had not identified human exposure data and lacked enough information to determine whether the compound would cause harm.
The 2026 briefing adds an identity warning. Different commercial substances can share the TB-500 name, creating a risk that a patient receives a different bulk drug substance than intended. For injectable products, sterility, endotoxins, concentration and storage stability add risks that an amino-acid sequence report does not address.
Mechanistic effects also deserve caution. Cell migration and angiogenesis can be useful in healing, but these pathways are not universally beneficial in every tissue or disease. Without controlled human data, it is not possible to define contraindications, interaction risks or a population in which benefits outweigh harms.
Thailand and anti-doping status
Do not treat online shipment or clinic availability as Thai approval. Use the official Thai FDA medicine search to look for the exact product and manufacturer. Because TB-500 naming is inconsistent, a qualified pharmacist should verify the active sequence and registration rather than relying on the front label.
WADA's position is explicit. The 2026 Prohibited List includes thymosin beta-4 and its derivatives, such as TB-500, under prohibited growth factors and growth-factor modulators. The prohibition applies at all times. Athlete testimonials are therefore both weak clinical evidence and a potential anti-doping warning sign.
A better injury-recovery checklist
For a tendon, muscle or wound problem, ask:
- What is the confirmed diagnosis and expected healing timeline?
- Which rehabilitation, wound-care or medical interventions improve function in human trials?
- Are there red flags for infection, rupture, poor blood supply or systemic disease?
- Which outcome matters: imaging, pain, strength, closure or return to activity?
- Does the proposed evidence study TB-500 itself in that condition?
This checklist keeps a molecular mechanism from displacing diagnosis and established care.
Common TB-500 content errors
- Calling the seven-amino-acid fragment full-length thymosin beta-4.
- Citing eye-drop trials as proof of injected injury recovery.
- Leaving the species out of a mouse wound-healing claim.
- Claiming "no side effects" when human exposure data are inadequate.
- Assuming every TB-500 label identifies the same chemical substance.
- Omitting WADA's explicit prohibition when writing for athletes.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. FDA describes TB-500 as an acetylated seven-amino-acid fragment corresponding to residues 17 to 23 of the 43-amino-acid thymosin beta-4 molecule; products sold under the common name can also be inconsistent.
Are there human trials proving that TB-500 heals injuries?
No. In its 2026 review, FDA found no clinical studies in which TB-500 itself was administered to patients to treat wounds or another condition.
Is TB-500 prohibited in sport?
Yes. WADA explicitly prohibits thymosin beta-4 and its derivatives, including TB-500, at all times.
Evidence-based conclusion
TB-500 has a plausible actin-related research story and positive preclinical wound findings. Its clinical story is fundamentally different: no established human efficacy data, unresolved product identity and limited safety information. A person with an injury should prioritize diagnosis and human-tested rehabilitation or wound care. Compare this record with the separate limitations of BPC-157 before discussing experimental compounds with a licensed clinician.